AMSA COMBINATION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA UNSUITABLE FOR STANDARD ANTILEUKEMIC TREATMENT

被引：2
作者：
MASCHMEYER, G
WILLBORN, K
HEIT, W
机构：
[1] Department of Internal Medicine, Hematology and Oncology, Evangelisches Krankenhaus Essen-Werden, Essen
来源：
LEUKEMIA & LYMPHOMA | 1992年 / 8卷 / 4-5期
关键词：
AMSA; AML; CHEMOTHERAPY; CARDIAC CONTRAINDICATIONS;
D O I：
10.3109/10428199209051016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Forty-eight patients with acute myelogenous leukemia (AML) not eligible for anthracycline or mitoxantrone treatment, mostly due to cardiac contraindications, were given aggressive therapy using m-amsacrine (AMSA) in combination with conventional or high-dose cytarabine for remission induction. Twenty-nine patients (60.4%) responded to treatment, and complete remission was attained in 19 (39.6%), partial remission in 4 (8.3%) and death in bone marrow aplasia without detectable blasts in 6 patients (12.5%). Median time to granulocyte recovery was 32 days, median duration of relapse-free survival 199 days. One patient experienced a serious cardiac adverse event; nausea and vomiting were observed in 73%, diarrhea in 44%, and hepatoxicity in 29% of patients. All potentially AMSA-related side effects were fully reversible, and a lethal complication did not occur. It is concluded that combination chemotherapy with AMSA and Ara-C is also effective and tolerable in leukemic patients in whom cardiotoxic drugs are contraindicated.
引用
收藏
页码：365 / 369
页数：5
相关论文
共 28 条
  • [1] Buchner T.H., Urbanitz D., Hiddemann W., Ruhl H., Ludwig W.-D., Fischer J., Aul H.C., Vaupel H.A., Kuse R., Zeile G., Nowrousian M.R., Konig H.J., Walter M., Wendt F., Sodomann H., Hossfeld D.K., Von Paleske A., Loffler H., Gassmann W., Hellriegel K.P., Fulle H.H., Lunscken C.H., Emmerich B., Pralle H., Pees H.W., Pfreundschuh M., Bartels H., Koeppen H.M., Schwerdtfeger R., Donhuijsen-Ant R., Mainzer K., Bonfert B., Koppler H., Zurborn K.H., Ranft K., Thiel E., Heinecke A., Intensified induction
  • [2] Cassileth P.A., Begg C.B., Bennett J.M., Bozdech M., Kahn S.B., Weiler C., Glick J.H., A randomized study on the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia, Blood, 63, pp. 843-847, (1984)
  • [3] Champlin R., Jacobs A., Gale R.P., Boccia R., Elashoff R., Foon K., Zighelboim J., Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy, Lancet, 1, pp. 894-896, (1984)
  • [4] Gale R.P., Cline M.J., High remission-induction rate in acute myeloid leukaemia, Lunrer, 1, pp. 497-499, (1977)
  • [5] Glucksberg H., Cheever M.A., Farewell V.T., Fefer A., Sale G.E., Thomas E.D., High-dose combination chemotherapy for acute non lymphoblastic leukemia in adults, Cancer, 48, pp. 1073-1081, (1981)
  • [6] Hayat M., Jehn U., Willemze R., Haanen C., Zittoun R., Monconduit M., Lowenberg B., Stryckmans P., Peetermans M., De Cataldo F., Kerkhofs H., Abels J., Klein H.O., Andrien J., Goudsmit R., Cauchie C., Suciu S., Solbu G.A., A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult myelogenous leukemia. A leukemia-lymphoma group trial of the EORTC, Cuncer, 58, pp. 617-623, (1986)
  • [7] Preisler H., Davis R.B., Kirshner J., Dupre E., Richards F., Hoagland C., Kopel S., Levy R.N., Carey R., Schulman P., Gottlieb A.J., McIntyre R., Comparison of thrcc remission induction regimens and two post induction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study, Blood, 69, pp. 1441-1449, (1987)
  • [8] Rai K.R., Holland J.K., Glidewell O.J., Weinberg V., Brunner K., Obrecht J.P., Preisler H.D., Nawabi I.W., Prager D., Carey R.W., Cooper M.R., Haurani F., Hutchinson J.L., Silver R.T., Falkson G., Wiernik P., Hoagland H.C., Bloomfield C.D., James G.W., Gottlieb A., Ramanan S.V., Blom J., Nissen N.I., Bank A., Ellison R.R., Kung F., Henry P., McIntyre O.R., Kaan S.K., Treatment of acute myelocytic leukemia: A study by Cancer and Leukemia Group B, Blood, 58, pp. 1203-1212, (1981)
  • [9] Rees J.K.H., Gray R.G., Swirsky D., Hayhoe F.G.J., Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial, Lancet, 11, pp. 1236-1241, (1986)
  • [10] Sauter C., Berchtold W., Fopp M., Imbach P., Tschopp L., Gratwohl A., Maurice P., Von Fliedner V., Cavalli F., Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival, Lancet, 1, pp. 379-382, (1984)
123